AA
PBYI icon

AlphaCentric Advisors’s Puma Biotechnology PBYI Stock Holding History

AlphaCentric Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$212K – 216
2022
Q4 		$212K Sell
50,000
-365,000
-88% -$1.26M 0.21% 129
2022
Q3 		$984K Buy
+415,000
New +$1.21M 1.01% 24
2021
Q4 		$1.22M Buy
400,000
+251,500
+169% +$1.09M 0.35% 21
2021
Q3 		$1.04M Buy
148,500
+108,500
+271% +$812K 0.26% 27
2021
Q2 		$367K Buy
40,000
+20,000
+100% +$203K 0.1% 80
2021
Q1 		$194K Buy
20,000
+10,500
+111% +$117K 0.07% 95
2020
Q4 		$97K Buy
+9,500
New +$96.2K 0.04% 140

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

AlphaCentric Advisors's PBYI Position: Q1 2023 in Review

AlphaCentric Advisors sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 50,000 shares — an estimated $212K sold.

AlphaCentric Advisors first reported a position in PBYI in Q4 2020 and held it in 7 quarters. The position peaked at $1.22M in Q4 2021. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • AlphaCentric Advisors reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 50,000 Puma Biotechnology shares in Q1 2023, an estimated $212K.
  • AlphaCentric Advisors first reported a position in Puma Biotechnology in Q4 2020 and held it in 7 quarters.
  • AlphaCentric Advisors's Puma Biotechnology position peaked at $1.22M in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on AlphaCentric Advisors's 13F filing for Q1 2023, filed 12 May 2023.